LAURUSLABS - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.2
| Stock Code | LAURUSLABS | Market Cap | 72,540 Cr. | Current Price | 1,343 ₹ | High / Low | 1,374 ₹ |
| Stock P/E | 98.0 | Book Value | 97.3 ₹ | Dividend Yield | 0.15 % | ROCE | 15.9 % |
| ROE | 15.1 % | Face Value | 2.00 ₹ | DMA 50 | 1,162 ₹ | DMA 200 | 997 ₹ |
| Chg in FII Hold | -0.70 % | Chg in DII Hold | 1.54 % | PAT Qtr | 192 Cr. | PAT Prev Qtr | 175 Cr. |
| RSI | 77.1 | MACD | 69.5 | Volume | 17,58,067 | Avg Vol 1Wk | 20,51,857 |
| Low price | 586 ₹ | High price | 1,374 ₹ | PEG Ratio | -110 | Debt to equity | 0.40 |
| 52w Index | 96.1 % | Qtr Profit Var | -23.9 % | EPS | 13.7 ₹ | Industry PE | 30.5 |
📊 Core Financials: Laurus Labs reports quarterly PAT at ₹192 Cr (up from ₹175 Cr), showing growth but with a -23.9% profit variation. ROE at 15.1% and ROCE at 15.9% indicate moderate efficiency. Debt-to-equity ratio of 0.40 is manageable, though margins are under pressure. EPS stands at ₹13.7, reflecting limited earnings expansion relative to valuation.
💹 Valuation Indicators: Stock P/E of 98.0 is far above the industry average (30.5), suggesting overvaluation. Book value at ₹97.3 vs CMP ₹1,343 highlights stretched valuations. PEG ratio of -110 signals weak earnings growth relative to price. Intrinsic value appears lower than CMP, limiting near-term upside potential.
🏭 Business Model & Advantage: Laurus Labs operates in pharma APIs and formulations with strong R&D and backward integration. Competitive advantage lies in scale, diversified product lines, and partnerships. Despite operational strengths, valuations remain a concern.
📈 Entry Zone & Holding Guidance: The stock trades near its 52-week high (₹1,374). RSI at 77.1 indicates overbought conditions. A better entry zone would be closer to DMA 200 (~₹997) or below ₹1,100. Long-term holding is viable given industry tailwinds, but fresh entry at current levels is risky.
Positive
- ✅ Strong ROE (15.1%) and ROCE (15.9%) efficiency
- ✅ Diversified pharma portfolio with R&D strength
- ✅ DII holdings increased by 1.54%, showing domestic institutional confidence
Limitation
- ⚠️ Extremely high P/E (98.0) vs industry average (30.5)
- ⚠️ Negative PEG ratio (-110), weak earnings growth
- ⚠️ Overbought RSI (77.1), limited short-term upside
Company Negative News
- 📉 Quarterly profit variation -23.9% indicates margin pressure
- 📉 FII holding decreased by 0.70%, showing reduced foreign investor confidence
Company Positive News
- 📈 PAT growth from ₹175 Cr to ₹192 Cr quarter-on-quarter
- 📈 Strong demand in pharma APIs and formulations supported by backward integration
Industry
- 🌐 Pharma industry PE at 30.5, indicating sector stability
- 🌐 Long-term demand for APIs and formulations remains strong globally
Conclusion
🔎 Laurus Labs is fundamentally strong with efficient returns and a robust business model. However, valuations are stretched, making current levels risky for fresh entry. Ideal entry would be near ₹1,000–₹1,100. Long-term investors may hold, but new investors should wait for correction before buying.
For deeper insights, you could explore a peer comparison or a valuation analysis to see how it stacks up against competitors and intrinsic value.